Related Experiment Videos
Ursodeoxycholic acid in chronic liver disease
J S de Caestecker1, R P Jazrawi, M L Petroni
1Department of Medicine, St George's Hospital Medical School, London.
Gut
|September 1, 1991
Summary
Ursodeoxycholic acid effectively reduces cholestasis and liver damage markers in chronic liver diseases. Further research is needed to confirm if early treatment improves long-term patient outcomes.
Area of Science:
- Hepatology
- Gastroenterology
- Pharmacology
Background:
- Chronic liver diseases are characterized by cholestasis and hepatocellular damage.
- Ursodeoxycholic acid (UDCA) is a hydrophilic bile acid with potential therapeutic benefits.
- Existing evidence supports UDCA's efficacy in specific cholestatic conditions.
Purpose of the Study:
- To evaluate the effectiveness of ursodeoxycholic acid in managing chronic liver diseases.
- To explore the mechanisms of action of UDCA in reducing liver injury.
- To assess the potential long-term impact of UDCA treatment.
Main Methods:
- Review of placebo-controlled trials and earlier uncontrolled observations.
- Analysis of biochemical markers of cholestasis and hepatocellular damage.
- Investigation into UDCA's mechanism involving bile acid pool modulation and bile flow.
Main Results:
- UDCA reduces biochemical markers of cholestasis and hepatocellular damage.
- Strongest evidence exists for primary biliary cirrhosis, primary sclerosing cholangitis, and cystic fibrosis-related cholestasis.
- Benefits may be limited in advanced liver disease stages.
Conclusions:
- Ursodeoxycholic acid is a valuable treatment for chronic cholestatic liver diseases, particularly primary biliary cirrhosis.
- UDCA improves cholestasis, reduces liver damage, and is well-tolerated.
- Future research should focus on early UDCA initiation to determine long-term prognostic improvements.